Funder Adds New Directors At GTC
As part of a funding agreement, GTC Biotherapeutics Inc. of Framingham has appointed Evelyne Nguyen, Jean-François Prost, Bertrand Merot, and William Heiden as directors, replacing four other board members.
LFB Biotechnologies of France appointed the new directors. Under a funding agreement, it has the right to appoint a number of directors commensurate with its ownership of GTC.
All the new directors are associated with LFB and its parent company, LFB SA. Prost is chief medical and scientific officer of LFB, Nguyen is director of financial affairs and strategy for LFB, Merot is COO of LFB Biotechnologies and Heiden is an outside director of LFB Biotechnologies and is managing director of Vitruvian Pharmaceuticals.
Resigning from the board to make room for the new additions are Robert Baldridge, Kenneth Bauer, Mary Ann Gray and Marvin Miller.
GTC is the developer of ATryn, an anti-inflammatory drug produced from the milk of genetically modified goats.
WBJ Web Partners
Most Recent
Most Recent
0 Comments